Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

SLAMF5 blocking of sorted Bregs CD19+IL10+ (GFP+)

ABSTRACT: SLAMF5 blocking of sorted Bregs CD19+IL10+ (GFP+)

PROVIDER: PRJNA674605 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR12979794.fastq.gz	Fastqsanger.gz
	SRR12979795.fastq.gz	Fastqsanger.gz
	SRR12979796.fastq.gz	Fastqsanger.gz
	SRR12979797.fastq.gz	Fastqsanger.gz

Items per page:

1 - 4 of 4

Similar Datasets

SLAMF5 blocking of sorted Bregs CD19+IL10+ (GFP+)

Project description:Purpose: Our results show that in the absence of SLAMF5 ( by KO or blocking ab), there is an accumulation of Bregs (CD19+IL10+) and a specific increase of their survival. Here, using RNAseq, we wished to identify genes that take place in the regulation of Breg by SLAMF5 blocking. Method: Total RNA was extracted from 3x10e5 sorted CD19+GFP+cells from 2-3 Vert-x mice (induced with EAE) incubated with SLAMF5 blocking Ab or control IgG using the Direct-zol RNA kit (ZymoResearch) according to the manufacturer’s instructions. RNA-seq was performed using the MARS-seq protocol. Showing here 2 biological replicates of each group.

2021-01-25 | GSE160828 | GEO

Single Cell analysis of Cells from a IL10 B cell conditional KO Kidneys

Project description:CD45+ Cells were sorted from kidneys from IL10 Fl/FL CD19 Cre mice or controls and analysed by 10x

2023-09-20 | GSE184794 | GEO

PPARδ inhibition blocks tumor-induced Bregs and enhances CD40 agonist immunotherapy

Project description:Most cancers are cold tumors characterized by a lack of effector T cells and hence unresponsive to immune checkpoint blockades, highlighting the importance of repairing the failed T cell priming in cancer immunotherapy. CD40 agonists are efficient in eliciting T cell responses and effective in converting cold tumors into hot, their clinical application, however, is limited by the very narrow window between the effective and toxic dosages. Here, we sought to reduce the effective dosage of CD40 agonists by combination therapy. We identified a CD19+CD24hiCD38lowIgDlow/- regulatory B cell (Breg) subset that is increased in tumor-bearing mice and cancer patients, and discovered that PPARδ is highly expressed in these tumor-associated Bregs and required for their proliferation and function. Inhibition of PPARδ acted synergistically with agonist anti-CD40 to enhance antitumor immunity without increasing toxicity in murine melanoma and bladder carcinoma models. Combination therapy with PPARδ inhibitor could reduce anti-CD40 dosage by over 60% to a well-tolerated level with improved or at least not compromised antitumor effects, providing a potential strategy for safely using CD40 agonists in cancer treatment. PPARδ also offers a new target for selectively blocking Breg activity while sparing immunostimulatory B cells that are known to aid antitumor immunotherapy.

2024-02-20 | GSE168523 | GEO

Characterization of Bregs-TLR/CpG by RNA-Seq

Project description:CpG-B cells and TLR-Bregs were obtained by giving isolated C57BL/6 splenic B cells either CpG ODN1668 stimulation for 3 days, or CpG stimulation with LPS, PMA, and ionomycin over the last 5 hours. RNA was extracted from all groups and analyzed using RNA-Sequencing and R.

2021-08-03 | GSE178713 | GEO

Gene expression profile at single cell level of in vitro induced regulatory B cells expressing granzyme B (GZMB+Bregs) and non-Bregs from healthy donors and kidney transplant recipients.

Project description:Regulatory B cells are considered as a very heterogenous population of different origins and functions. We used single cell RNA sequencing (scRNA-seq) to analyze the regulatory B cells expressing granzyme B (GZMB+Bregs).

2023-08-23 | GSE224460 | GEO

Gene expression in primary human bone marrow plasma cells sorted according to CD19 expression

Project description:To characterize human bone marrow plasma cells that express or lack CD19 on a molecular level, we compared the global gene expression of primary CD38high/CD138+ plasma cells with or without CD19 expression.

2014-12-31 | GSE56464 | GEO

Comparison of IL10-eGFP+ cells with IL10-eGFP- CD4+ T cells induced by in vivo immunisation

Project description:Here we perform QuantSeq 3' mRNA sequencing of RNA extracted from flow sorted splenic CD4+ Il10-eGFP+ or CD4+Il10eGFP- T cells from Tg4 Nr4a3-Tocky Il10-eGFP mice 24 hours after immunisation with 4 mg/kg of [4Y]-MBP. Our aim was to confirm the Tr1 cell phenotype within the Il10-eGFP+ T cell subset

2024-12-09 | GSE283286 | GEO

Gene expression profile of CD4+ CD25- T cells in coculture with regulatory B cells expressing granzyme B (GZMB+Bregs) or total B cells

Project description:Regulatory B cells are considered as a very heterogenous population of different origin and functions. Here, we show that Notably, Bregs induced a strong inhibition of T cell genes associated to proliferation, activation, inflammation and apoptosis compared to total B cells. We identified and validated 5 receptor/ligand interactions between Bregs and T cells.

2023-08-23 | GSE224456 | GEO

Proteomic changes of CD19+ B Lymphocytes in COVID-19 Patients

Project description:The immune response to SARS-CoV-2 varies among patients. We used proteomic analysis to study CD19+ lymphocytes, which are important for the immune response. By comparing the proteomes of CD19+ cells from healthy individuals and COVID-19 patients, we discovered proteins and signaling pathways involved in the immune response during COVID-19. This knowledge improves our understanding of immune dysregulation in COVID-19 and can help develop targeted therapies. Our research also explores the role of CD19+ lymphocytes in COVID-19 and identifies potential biomarkers. Overall, our findings contribute to understanding COVID-19 immunology and inform future research efforts.

2023-09-24 | PXD042938 | Pride

IL10 Chicken Project

Project description:16S analysis of caecal contents of IL10 chicken

| PRJEB71960 | ENA